Recently, the Finerenone Tablets (English trade name: Kerendia, Chinese trade name: 可申达) is approved for marketing by NMPA in China, which is an innovative drug of Bayer. The drug is indicated for the treatment of adults with chronic kidney disease associated with type 2 diabetes (estimated glomerular filtration rate [eGFR] of ≥ 25 to <75 mL/min/1.73 m2 with albuminuria) to reduce the risk of sustained eGFR decline and end-stage kidney disease.
Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. MR is expressed in the kidney, heart, and blood vessels, and Finerenone attenuates inflammation and fibrosis mediated by MR overactivation. This product provides a new treatment option available for adult patients with chronic kidney disease associated with type 2 diabetes.